علاج التهاب الكبد المناعي الذاتي لدى مرضى تشمع الكبد

References

DOI: 10.1002/hep.31065

• For children and adults with AIH who have cirrhosis or who present with acute severe AIH, the AASLD suggests that budesonide not be used (conditional recommendation, very low certainty).
• Patients with cirrhosis should not receive budesonide because portosystemic shunting may reduce drug efficacy and promote SSSE by allowing budesonide to bypass the liver.
• The ideal laboratory response is normalization of serum ALT, AST, and IgG levels.
• The rapidity of response to treatment is the most important index of outcome, and the serum aminotransferase levels should improve within 2 weeks.